Australia limits use of AstraZeneca 19 vaccine to people over 60

SYDNEY/CANBERRA, June 17 (Reuters) - Australia will recommend only people over 60 receive AstraZeneca's AZN.L COVID-19 vaccine, the country's Minister for Health Greg Hunt said on Thursday, following a spate of blood clots in those who have received the inoculation.

Australia has administered 3.3 million doses of the AstraZeneca vaccine, and it has been linked to 60 cases of blood clots, the government has said. So far, two people have died, which Hunt said has driven the policy shift.

"The government places safety above all else," Hunt told reporters in Canberra.

"This updated advice received today is based on new evidence demonstrating a higher risk for the very rare (thrombocytopenia syndrome) condition in the 50-59 year-old age group."

Australia in April moved to limit the use of the AstraZeneca vaccine to people over 50 years old.

Several European Union member states have stopped administering the AstraZeneca vaccine to people below a certain age, usually ranging from 50 to 65, restricting its use to older people, due to very rare cases of blood clotting, mainly among young people.

Hunt said the recommendation would not delay its inoculation timetable, which has a target of giving at least one COVID-19 vaccine dose to every Australian before the end of 2021.

Australia in April expanded its order of Pfizer's PFE.N COVID-19 vaccine to 40 million doses, while it has also ordered 25 million shots from Moderna MRNA.O .

Australia's amended vaccine policy comes as the country's most populous state battles to contain a cluster of COVID-19 cases.

New South Wales said it now recorded four local cases of COVID-19, with the source of the outbreak still unclear.

"At this stage, we are all on high alert," NSW state Premier Gladys Berejiklian told reporters in Sydney.

A man in his 60s, who works as a driver for international airline crews, was detected with the virus on Wednesday, the state's first case in more than a month, and his wife has since tested positive. Genetic tests found the man has the Delta virus strain, officials said.

The Delta variant, which has been classified by the World Health Organisation (WHO) as among the four COVID-19 variants of concern due to evidence that they spread more easily, likely caused the latest devastating outbreak in India.

Nearly a dozen venues in Sydney including a cinema in a shopping centre in the popular tourist spot of Bondi and a supermarket have been listed as virus hotspots.

Australia has successfully suppressed past outbreaks through snap lockdowns, swift contact tracing and tough social distancing rules. It has reported just under 30,300 cases and 910 deaths since the pandemic began.
Reporting by Renju Jose in Sydney and Colin Packham in Canberra; Editing by Raju Gopalakrishnan

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.